Doxorubicin causes cachexia, sarcopenia, and frailty characteristics in mice
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0301379 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Paola Sanches Cella und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physical Education, State University of Londrina, Londrina, Paraná, Brazil. Hauptthemen laut MEDLINE: Doxorubicin, Cachexia, Sarcopenia, Frailty. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Fundação Araucária.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
While chemotherapy treatment can be lifesaving, it also has adverse effects that negatively impact the quality of life. To investigate the effects of doxorubicin chemotherapy on body weight loss, strength and muscle mass loss, and physical function impairments, all key markers of cachexia, sarcopenia, and frailty. Seventeen C57/BL/6 mice were allocated into groups. 1) Control (n = 7): mice were exposed to intraperitoneal (i.p.) injections of saline solution. 2) Dox (n = 10): mice were exposed to doxorubicin chemotherapy cycles (total dose of 18 mg/kg divided over 15 days). The body weight loss and decreased food intake were monitored to assess cachexia. To assess sarcopenia, we measured muscle strength loss using a traction method and evaluated muscle atrophy through histology of the gastrocnemius muscle. To evaluate physical function impairments and assess frailty, we employed the open field test to measure exploratory capacity. Doxorubicin administration led to the development of cachexia, as evidenced by a significant body weight loss (13%) and a substantial decrease in food intake (34%) over a 15-day period. Furthermore, 90% of the mice treated with doxorubicin exhibited sarcopenia, characterized by a 20% reduction in traction strength (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Physical Education, State University of Londrina, Londrina, Paraná, Brazil.
- Laboratory of Chemistry, State University of Londrina, Londrina, Paraná, Brazil.
- The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
- Laboratory of Applied Biomechanics State University of Londrina, Londrina, Paraná, Brazil.
- Laboratory of Animal Pathology, State University of Londrina, Londrina, Paraná, Brazil.
ORCID-Profile: Paola Sanches Cella, Patricia Chimin
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Fundação Araucária
Zitieren
APA
Cella, P. S., Matos, R. L. N., Marinello, P. C., Costa, J. C. D., Moura, F. A., Bracarense, A. P. F. R. L., Chimin, P., & Deminice, R. (2024). Doxorubicin causes cachexia, sarcopenia, and frailty characteristics in mice. PLOS ONE. https://doi.org/10.1371/journal.pone.0301379
Vancouver
Cella PS, Matos RLN, Marinello PC, Costa JCD, Moura FA, Bracarense APFRL, et al. Doxorubicin causes cachexia, sarcopenia, and frailty characteristics in mice. PLOS ONE. 2024. doi:10.1371/journal.pone.0301379
BibTeX
@article{Cella2024,
author = {Cella, Paola Sanches and Matos, Ricardo Luís Nascimento de and Marinello, Poliana Camila and Costa, Júlio Cesar da and Moura, Felipe Arruda and Bracarense, Ana Paula Frederico Rodrigues Loureiro and Chimin, Patricia and Deminice, Rafael},
title = {Doxorubicin causes cachexia, sarcopenia, and frailty characteristics in mice},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0301379}
}
EUVIMED